Quality & Compliance

Changes are coming to Annex 1 of the EU’s GMP. What can pharma expect?

Building and managing an advanced therapy collection network is a significant challenge, but there is another route.

To keep biosimilars costs as low as possible, take a good look at your purification and characterization processes.

Simple and efficient systems for continuous monitoring can make all the difference in developing innovative products.

AI is expanding into medicine. Are the world’s regulators ready?

What are the challenges and best practices in quality control for difficult-to-inspect products?

Sandoz’s Pierre Bourdage talks to us about biosimilars and how uptake can be boosted.

How a holistic approach to horseshoe crab sustainability will allow the industry to maintain stocks while protecting patients.

How can we ease the process of taking ATMPs to clinical trials? Two experts lay out the key considerations.

Creating a patient-centric ecosystem in India.